End-of-day quote
Other stock markets
|
||
- USD | - |
05-14 | CV Sciences Seeks M&A Opportunities | CI |
05-14 | Transcript : CV Sciences, Inc., Q1 2024 Earnings Call, May 14, 2024 |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Herb-based Supplements and Hemp-based Cannabidiol
100.0
%
| 16 | 100.0 % | 16 | 100.0 % | -1.24% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 16 | 100.0 % | 16 | 100.0 % | -1.24% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Joseph Dowling
CEO | Chief Executive Officer | 66 | 15/06/14 |
Joerg Grasser
DFI | Director of Finance/CFO | 49 | 25/12/18 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Dowling
CEO | Chief Executive Officer | 66 | 15/06/14 |
Jamie Corroon
BRD | Director/Board Member | 54 | 20/07/22 |
William McCorkle
BRD | Director/Board Member | 56 | 20/10/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 163,228,469 | 163,197,469 ( 99.98 %) | 0 | 99.98 % |
Stock B | 0 | 1,000 | 0 | 0 |
Company contact information
CV Sciences, Inc.
9530 Padgett Street Suite 107
92126, San Diego
+866 290 2157
http://www.cvsciences.comSector
1st Jan change | Capi. | |
---|---|---|
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- CVSI Stock
- Stock
- Company CV Sciences Inc